Evidence map›Paper›PMID 32391667›Full record

Trial reportZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences2020

[A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19].

Jun Chen, Danping Liu, Li Liu, Ping Liu, Qingnian Xu, Lu Xia, Yun Ling, Dan Huang, Shuli Song, Dandan Zhang and 4 more

3 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 397 papers, 30 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
397citing papers in PubMed, 30 pooled it
17.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04261517 phase3completednot on this map

Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19

TypeinterventionalSponsorShanghai Public Health Clinical CenterRan2020 to 2020Enrolled30ConditionsPneumonia, Pneumocystis, Coronavirus, COVID-19ArmsHydroxychloroquine
NCT04491994 phase3completednot on this map

Clearing the Fog: Is HCQ Effective in Reducing COVID-19 progression-a Randomized Controlled Trial

TypeinterventionalSponsorUNICEFRan2020 to 2020Enrolled540ConditionsCovid19, ProgressionArmsHCQ
NCT05808231 naunknown statusnot on this mapstarted 2021, after this paper: background citation

An aDaptive, multicEnter, rAndomized, Open-Label, Controlled Trial to Assess Effectiveness and Safety of Quinine Sulfate for COVID-19 in Hospitalized Adults

TypeinterventionalSponsorUniversitas PadjadjaranRan2021 to 2023Enrolled100ConditionsCOVID-19ArmsStandard of Care + Quinine Sulfate, Standard of Care
3 · Its place in the literature

Who cites it

397 citing papers in PubMed, 30 syntheses or guidelines pooled it, 703 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2021
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Guideline
  15. Pooled it
  16. Pooled it
  17. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.The Cochrane database of systematic reviews · 2021
    Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

337 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Jun ChenDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Danping LiuDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Li LiuDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Ping LiuDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Qingnian XuDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Lu XiaDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Yun LingDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Dan HuangDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Shuli SongDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Dandan ZhangDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Zhiping QianDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Tao LiDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Yinzhong ShenDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Hongzhou LuDepartment of Infection and Immunity, Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Shanghai Public Health Clinical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the treatment of patients with moderate coronavirus disease 2019 (COVID-19).

methodsWe prospectively enrolled 30 treatment-naïve patients with confirmed COVID-19 after informed consent at Shanghai Public Health Clinical Center. The patients were randomized 1：1 to HCQ group and the control group. Patients in HCQ group were given HCQ 400 mg per day for 5 days plus conventional treatments, while those in the control group were given conventional treatment only. The primary endpoint was negative conversion rate of SARS-CoV-2 nucleic acid in respiratory pharyngeal swab on days 7 after randomization. This study has been approved by the Ethics Committee of Shanghai Public Health Clinical Center and registered online (NCT04261517).

resultsOne patient in HCQ group developed to severe during the treatment. On day 7, nucleic acid of throat swabs was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group (

conclusionsThe prognosis of COVID-19 moderate patients is good. Larger sample size study are needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent research should determine better endpoint and fully consider the feasibility of experiments such as sample size.

Indexed as

BetacoronavirusHydroxychloroquineChinaCoronavirus InfectionsCOVID-19HumansPandemicsPilot ProjectsPneumonia, ViralRNA, ViralSARS-CoV-2Treatment OutcomeHydroxychloroquineRNA, Viral

Identifiers

PMID32391667
PMCPMC8800713
OpenAlexW3010992334

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.